Keeping the immuno-oncology flame burning

Abstract

Ira Mellman, the new president of research at the Parker Institute for Cancer Immunotherapy, asks why so many drug developers are retreating from immune-modulating drugs, cell therapies and cancer vaccines before these modalities have achieved their full potential.